AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia

by NASDAQ Market News November 22, 2021

NASDAQ Market News
Click here to email author

Cullinan Oncology to Participate in the Evercore ISI 4th Annual HealthconX Conference

Quipt Announces Execution of LOI to Acquire Leader in Comprehensive Respiratory Care Within the Long-Term Care Setting With Approximately $14 Million in Annualized Revenue and $1 Million in Net Income

Ads